Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
doi:10.1016/j.molmet.2020.101102 Antza C, Nirantharakumar K, Doundoulakis I, Tahrani AA, Toulis KA
This is the frustrating reality for millions of people
Ex(9-39) did not produce any effect on locomotion (Fig
Recent Developments: Roche - Acquisition (December 2023): Roche acquired Carmot Therapeutics, adding dual GLP-1/GIP agonist assets to its pipeline, positioning to compete with Novo Nordisk and Eli Lilly in obesity [1]
doi: 10.1210/en.2014-1675 52 AlvarezEMartinezMDRonceroIChowenJAGarcia-CuarteroBGispertJDet al
US$ 25.02
US$ 28.00
US$ 26.71
US$ 22.95
